直肠癌机器人手术方案的比较:两个腹腔镜与机器人参考中心之间的回顾性比较研究的短期和长期结果
该回顾性比较研究纳入两个结直肠外科中心2015至2021年间收治的197例直肠癌患者,其中腹腔镜辅助切除术(LAR)组占70%、机器人辅助手术(RAS)组占30%,比较围手术期并发症、短期和长期肿瘤学及功能结局。结果显示RAS组环周切缘R1率显著低于LAR组(2% vs 13%,p=0.009),但LAR组前切除综合征发生率显著低于RAS组(54% vs 76%,p=0.030),两组总体术后死亡率、并发症率、30天内早期再手术率、完整TME率及3年复发率均无显著差异。作者结论认为RAS在肿瘤学结局和并发症方面可靠,但未观察到预期的功能结局获益,需结合新的腹腔镜技术和患者管理选项重新评估RAS的附加价值。
要点
- RAS组环周切缘R1率显著低于LAR组(2% vs 13%,p=0.009)。
- LAR组前切除综合征发生率显著低于RAS组(54% vs 76%,p=0.030)。
- 两组术后死亡率、并发症率、再手术率、完整TME率及3年复发率均无显著差异。
核心结论
- RAS用于直肠癌在肿瘤学结局和并发症方面可靠,但未观察到预期的功能结局获益,需结合新的腹腔镜技术和患者管理选项重新评估其附加价值。
研究设计与样本
- 回顾性比较研究,纳入两个结直肠外科中心2015至2021年间收治的197例直肠癌患者,LAR组占70%、RAS组占30%。
主要发现
- 总体术后死亡率两组无显著差异(LAR组0% vs RAS组0.5%,无显著差异)。
- 术后并发症率两组相似(LAR组60% vs RAS组57%,无显著差异)。
- 30天内早期再手术率两组相似(LAR组10% vs RAS组3%,无显著差异)。
- 完整TME率两组相似(LAR组88% vs RAS组94%,无显著差异)。
- 环周切缘R1率LAR组显著高于RAS组(13% vs 2%,p=0.009)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is assumed that robotic-assisted surgery (RAS) may facilitate complex pelvic dissection for rectal cancer compared to the laparoscopic-assisted resection (LAR). The aim of this study was to compare perioperative morbidity, short- and long-term oncologic, and functional outcomes between the RAS and LAR approaches. METHODS: Between 2015 and 2021, all rectal cancers operated on by (LAR) or (RAS) were retrospectively reviewed in two colorectal surgery centers. RESULTS: A total of 197 patients were included in the study, with 70% in the LAR group and 30% in the RAS group. The tumor location and stage were identical in both groups (not significant = NS). The overall postoperative mortality rate was not significantly different between the two groups. (0% LAR; 0.5% RAS; NS). The postoperative morbidity was similar between the two groups (60% LAR vs 57% RAS; NS). The number of early surgical re-interventions within the first 30 days was similar (10% for the LAR group and 3% for the RAS group; NS). The rate of complete TME was similar (88% for the LAR group and 94% for the RAS group; NS). However, the rate of circumferential R1 was significantly higher in the LAR group (13%) compared to the RAS group (2%) (p = 0.009). The 3-year recurrence rate did not differ between the two groups (77% for both groups; NS). After a mean follow-up of three years, the incidence of anterior resection syndrome was significantly lower in the LAR group compared to the RAS group (54 vs 76%; p = 0.030). CONCLUSIONS: The use of a RAS was found to be reliable for oncologic outcomes and morbidity. However, the expected benefits for functional outcomes were not observed. Therefore, the added value of RAS for rectal cancer needs to be reassessed in light of new laparoscopic technologies and patient management options.
引用
- Rogier-Mouzelas F, Piquard A, Karam E, et al. Comparison of a robotic surgery program for rectal cancer: short- and long-term results from a comparative, retrospective study between two laparoscopic and robotic reference centers. Surg Endosc. 2024. PMID: 38789622. doi:10.1007/s00464-024-10867-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。